Description: Based on science from Umeå university, the focus of Asarina Pharma is development of pharmaceuticals to treat unwanted effects of GABA-steroids that acts on the central nervous system. Asarina Pharma develops a new treatment for Premenstrual Dysphoric Disorder, which is the most severe form of PMS and has now one of its compounds in clinical testing in patients.
CEO: Gunilla Lundmark
Pharmanest is a pharmaceutical company specialized in developing products for local pain relief in obstetrics and gynecology.
Pharmanest was founded in 2009 and is based on research about pain innervation of the cervix and uterus carried out by Dr. Berith Karlsson Tingåker, obstetrician, Stockholm, Dr. Gunvor Ekman-Ordeberg, professor of obstetrics and gynecology, Karolinska Institutet, and Dr. Lars Irestedt, associate professor and anesthesiologist at Karolinska Hospital.
The business concept is to use known substances to develop, patent
and clinically evaluate new products for local application where pain relief is
Our vision is to make pain relief available to all women using safe and effective products for local application where pain relief is needed. Pain relief in gynecological
procedures such as curettage after miscarriage and during labor and delivery
are essentially only available to a small percentage of women worldwide.
Our unique combination of clinical expertise, based on close local collaboration with specialists and other partners at universities, along with Pharmanest’s expertise in product development, is the source of Pharmanest’s strength.
Pharmanest is one of the companies within Karolinska Development AB; office and
lab facilities are located within the Karolinska Institutet campus, providing
proximity to research, strong networks and a creative environment.
CEO: Lena Degling Wikingsson
The company develops New Chemical Entities by modifying heparin. Two of these Heparin are now in clinical phases of development; DF01 is intended for the prevention and treatment of slow progress of birth labour. DF02 is diminishing severe clinical manifestations in malaria.